FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Noven Pharmaceuticals Minivelle Recall

Minivelle (estradiol transdermal system) 0

Noven Pharmaceuticals, Inc. · Miami, FL

Risk level
Class II
Reported by FDA
May 16, 2018
Recall ID
D-0862-2018
Check your lot numberHow we source this data

Summary

Noven Pharmaceuticals recalled Minivelle starting May 4, 2018. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0862-2018 on May 16, 2018. Reason: Defective Delivery System: no longer meets the specification for shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin. Status: Terminated.

Why it was recalled

Defective Delivery System: no longer meets the specification for shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Product description

Minivelle (estradiol transdermal system) 0.1 mg/day, 1 System per pouch (NDC 68968-6610-1), packaged in 8 pouches per box (NDC 68968-6610-8), Rx only, Mfd. by: Noven Pharmaceuticals, Inc., Miami, Florida 33186; Dist. by: Noven Therapeutics, LLC, Miami, Florida 33186.

Lot numbers, UPCs & expiration codes

Lot #: 81391, 81638 Exp. 10/18

Where it was sold

Nationwide in the USA.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0862-2018
Classification
Class II
Status
Terminated
Recall initiated
May 4, 2018
FDA report date
May 16, 2018
Quantity
61960 boxes
Recall type
Voluntary: Firm initiated
Recalling firm
Noven Pharmaceuticals, Inc.

Original FDA data

Every field from FDA enforcement report D-0862-2018, exactly as published.

Show all FDA fields
City
Miami
State
FL
Status
Terminated
Country
United States
Event ID
80033
Address
11960 SW 144th St
Code information
Lot #: 81391, 81638 Exp. 10/18
Postal code
33186-6109
Report date
May 16, 2018
Product type
Drugs
Recall number
D-0862-2018
Classification
Class II
Recalling firm
Noven Pharmaceuticals, Inc.
Product quantity
61960 boxes
Termination date
Jun 4, 2020
Reason for recall
Defective Delivery System: no longer meets the specification for shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Minivelle (estradiol transdermal system) 0.1 mg/day, 1 System per pouch (NDC 68968-6610-1), packaged in 8 pouches per box (NDC 68968-6610-8), Rx only, Mfd. by: Noven Pharmaceuticals, Inc., Miami, Florida 33186; Dist. by: Noven Therapeutics, LLC, Miami, Florida 33186.
Distribution pattern
Nationwide in the USA.
Recall initiation date
May 4, 2018
Initial firm notification
Letter
Center classification date
Jun 13, 2018

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0862-2018, published May 16, 2018. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls